BCM
MBVX

Biomark Capital Management’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Biomark Capital Management’s Portfolio MBVX Stock Details MBVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$4K Hold
8,903
– – 0.04% 2
2018
Q2 		$8K Hold
8,903
– – 0.12% 2
2018
Q1 		$13K Hold
8,903
– – 0.2% 2
2017
Q4 		$19K Hold
8,903
– – 0.02% 3
2017
Q3 		$17K Hold
8,903
– – 0.02% 3
2017
Q2 		$37K Hold
8,903
– – 0.06% 3
2017
Q1 		$61K Hold
8,903
– – 0.11% 3
2016
Q4 		$90K Hold
8,903
– – 0.19% 3
2016
Q3 		$113K Buy
+8,903
New +$134K 0.15% 3

Other funds holding MBVX

PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Biomark Capital Management's MBVX Position: Q3 2018 in Review

Biomark Capital Management held its MABVAX THERAPEUTICS HLDGS INC (MBVX) position steady in Q3 2018 at 8,903 shares worth $4K. The position accounts for 0.04% of the portfolio, ranked #2.

Biomark Capital Management first reported a position in MBVX in Q3 2016 and has held it in 9 quarters since. The position peaked at $113K in Q3 2016. 2 funds tracked by Wall St. Rank hold MBVX as of Q3 2018.

  • Biomark Capital Management held 8,903 shares of MABVAX THERAPEUTICS HLDGS INC worth $4K as of Q3 2018.
  • Biomark Capital Management left its MABVAX THERAPEUTICS HLDGS INC share count unchanged in Q3 2018.
  • MABVAX THERAPEUTICS HLDGS INC made up 0.04% of Biomark Capital Management's portfolio in Q3 2018, its #2 holding.
  • Biomark Capital Management first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q3 2016 and has held it in 9 quarters since.
  • Biomark Capital Management's MABVAX THERAPEUTICS HLDGS INC position peaked at $113K in Q3 2016.
  • 2 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q3 2018.

Based on Biomark Capital Management's 13F filing for Q3 2018, filed 24 Oct 2018.